AVE 25.0% 0.3¢ avecho biotechnology limited

oxymorphone patch m eets phase 1 end points

  1. 34,916 Posts.
    lightbulb Created with Sketch. 480
    Oxymorphone delivered for 72 hours from single patch application with no adverse events

    Company to proceed with multi-dose and Phase 2 trials in H2 2013


    Hmm I thought they weren't doing Phase 2 trials?
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.